Skip to main content
. 2022 Oct 10;127(12):2141–2153. doi: 10.1038/s41416-022-02006-y

Fig. 2. FGF14-AS2 suppresses osteolytic metastasis via the RUNX2/RANKL axis.

Fig. 2

a, b RANKL levels in FGF14-AS2-overexpressing and FGF14-AS2-knockdown cells were detected using qRT‐PCR (a) and western blotting (b). c, d RUNX2 levels in FGF14-AS2-overexpressing and FGF14-AS2-knockdown cells were detected using western blotting (c) and qRT‐PCR (d). e RANKL levels in FGF14-AS2-overexpressing cells transfected with or without RUNX2 expression plasmids were detected using western blotting. f FGF14-AS2 expression plasmid was transiently transfected into MDA-MB-231 or MDA-MB-468 cells together with RUNX2 expression plasmid or pcDNA3.1 plasmid. RAW264.7 cells were stimulated with the indicated CM in the presence of RANKL (50 ng/mL). Cells were fixed and stained for TRAP activity (left), and the areas of TRAP-positive cells were analysed (right). Scale bar = 200 µm. g, h RUNX2 and RANKL levels in the tibiae of mice injected with FGF14-AS2 OE and control cells were detected by immunohistochemistry analysis (g) and western blotting (h). The data are shown as the mean ± s.d. of at least three independent experiments. **P < 0.005, ***P < 0.001 and ns, no significance.